Insider Selling: Outset Medical (NASDAQ:OM) CEO Sells $10,706.00 in Stock

Outset Medical, Inc. (NASDAQ:OM) CEO Leslie Trigg sold 2,120 shares of the firm’s stock in a transaction that occurred on Wednesday, January 21st. The stock was sold at an average price of $5.05, for a total value of $10,706.00. Following the transaction, the chief executive officer owned 105,703 shares in the company, valued at approximately $533,800.15. The trade was a 1.97% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Leslie Trigg also recently made the following trade(s):

• On Tuesday, January 20th, Leslie Trigg sold 11,794 shares of Outset Medical stock. The shares were sold at an average price of $5.12, for a total value of $60,385.28.
• On Wednesday, January 7th, Leslie Trigg sold 1,795 shares of Outset Medical stock. The shares were sold at an average price of $4.27, for a total value of $7,664.65.
• On Monday, November 17th, Leslie Trigg sold 916 shares of Outset Medical stock. The stock was sold at an average price of $4.60, for a total transaction of $4,213.60.

Outset Medical Trading Down 5.4%

NASDAQ:OM opened at $5.11 on Friday. The firm has a market capitalization of $92.75 million, a P/E ratio of -0.39 and a beta of 2.07. The company has a quick ratio of 5.77, a current ratio of 7.09 and a debt-to-equity ratio of 0.69. The company has a fifty day moving average of $4.35 and a 200 day moving average of $10.89. Outset Medical, Inc. has a 52 week low of $3.10 and a 52 week high of $21.98.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Assenagon Asset Management S.A. purchased a new position in shares of Outset Medical in the 3rd quarter valued at approximately $5,324,000. Geode Capital Management LLC boosted its holdings in shares of Outset Medical by 955.9% during the 2nd quarter. Geode Capital Management LLC now owns 415,552 shares of the company’s stock valued at $7,984,000 after buying an additional 376,196 shares in the last quarter. Pura Vida Investments LLC grew its position in shares of Outset Medical by 8,482.4% in the 2nd quarter. Pura Vida Investments LLC now owns 429,120 shares of the company’s stock worth $8,243,000 after buying an additional 424,120 shares during the period. Ensign Peak Advisors Inc increased its stake in shares of Outset Medical by 272.4% in the 2nd quarter. Ensign Peak Advisors Inc now owns 314,522 shares of the company’s stock worth $6,042,000 after acquiring an additional 230,065 shares in the last quarter. Finally, Citadel Advisors LLC increased its stake in shares of Outset Medical by 372.8% in the 3rd quarter. Citadel Advisors LLC now owns 96,084 shares of the company’s stock worth $1,357,000 after acquiring an additional 75,762 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. Royal Bank Of Canada reiterated a “sector perform” rating and set a $7.00 target price on shares of Outset Medical in a report on Wednesday, December 17th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Outset Medical in a report on Monday, December 29th. Wall Street Zen lowered Outset Medical from a “hold” rating to a “sell” rating in a research report on Saturday, January 10th. Stifel Nicolaus decreased their target price on Outset Medical from $14.00 to $8.00 and set a “buy” rating for the company in a report on Wednesday, January 7th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $17.00 price target on shares of Outset Medical in a research note on Tuesday, December 16th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $10.67.

Outset Medical Company Profile

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.